Tag: TB

09 Nov 2016

TB Alliance partners with PepsiCo

TB Alliance is a not-for-profit organisation dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. The organisation recently announced a partnership with beverage company PepsiCo with the sole purpose of improving the taste of treatment for children with TB.

“At PepsiCo, we saw a unique opportunity to leverage our R&D talent and flavor expertise to help improve the palatability of certain TB medicines,” said Dr. Mehmood Khan, Vice Chairman and Chief Scientific Officer, Global Research and Development, PepsiCo. “In collaboration with the TB Alliance team and others, we are hopeful that we can identify formulation changes that will make it easier for caregivers to administer TB medicines to children. Our work together has the potential to significantly improve the care and well-being of many TB patients and move us one step closer to the goal of eradicating TB in children.”

For the full story please visit : http://www.tballiance.org/news/tb-alliance-partners-pepsico-advance-fight-improved-medicines-children

[source : http://www.tballiance.org/]

03 Oct 2016

Exciting development in TB medicine for children

TB Alliance together with the Kenya Ministry of Health, UNITAID and others have released a range of new formulations of existing TB medicines tailored for children. The new medicines are easier to administer and this will hopefully increase the treatment and survival rate for children living with TB.

Kenya’s Cabinet Secretary for Health, Dr. Cleopa Mailu, explained: “Kenya is playing a leading role in the fight against childhood TB by being the first to introduce improved TB medicines for children. Now, with the appropriate treatments, we can make rapid progress in finding and treating children with TB so we can achieve a TB free generation.”

With current treatments, caregivers have to break, cut or crush multiple pills just to create the correct dosage for a child. Due to the effort involved and the bitter taste of these pills, treatment is difficult to keep up for the required 6 months, resulting in treatment failure and sometimes even death.

The new treatment consists of improved formulations which are available in the correct doses, are flavoured and is water soluble.

According to Dr. Cherise Scott, Director of Pediatric Programs for TB Alliance: “We are proud to partner with the Government of Kenya, the first of many countries, as they work to translate the potential of these medicines into lives saved.”

From 1 October 2016, all children starting on TB treatment in Kenya will be prescribed the new medicine. “Childhood TB is a problem that can be solved when we choose to act,” commented Dr. Enos Masini, Head of Kenya’s National Tuberculosis, Leprosy, and Lung Disease Program.

For more information on this, please go to: http://www.tballiance.org/news/kenya-becomes-first-country-introduce-new-child-friendly-tb-medicines

13 Sep 2016


Triclinium will for the third time participate in the annual VPM Days Conference in Hannover, Germany on 15th – 16th September 2016.

VPM is Vakzine Projekt Management, a public–private partnership venture founded jointly by the German Federal Ministry of Education and Research and the Braunschweig-based Helmholtz Centre for Infection Research in 2002.  Since 2009, Triclinium has collaborated with VPM as the managing CRO for three Phase I and II trials conducted in South Africa with their novel tuberculosis vaccine, VPM1002.

The VPM Days annual meeting brings together a wide group of organisations and academics involved in translation research and development.  Triclinium’s Managing Director will present a paper entitled “The regulatory landscape in South Africa and neighbouring countries: updates, challenges and opportunities.” Triclinium has become a regular contributor to this forum.  Mr. Strugo was also an invited presenter in 2015 preceded in 2012 by Tracy Southwood, at the time Triclinium’s Project Manager for VPM’s Phase I trial and currently Head of Business Development.

VPM1002 is a recombinant BCG vaccine co-developed by VPM and the Max Planck Society.  It was recently out-licensed to Serum Institute of India Ltd, the world’s largest vaccine manufacturer, which will also be represented at the VPM Days this year.  The full conference programme is at http://www.vakzine-manager.de

22 Jun 2016

New Memorandum of Understanding between TB Alliance and the Medicines Patent Pool to Improve Access to TB Medicines in Resource-Limited Countries

TB Alliance and the Medicines Patent Pool signed a Memorandum of Understanding in April 2016, outlining a multi-faceted plan to encourage the development of affordable new TB (tuberculosis) regimens and ensure their availability in low-and-middle income countries.

TB is currently the deadliest infectious disease globally, killing one person every 20 seconds, the majority of cases being in low-resource settings. Making the pandemic worse is the growing number of patients who are co-infected with HIV, as well as the emergence of multi-drug resistant (MDR-) and extensively drug-resistant (XDR-) TB. The current TB treatment regimens are long, demanding and costly, improved, faster-acting and more affordable treatment is necessary to halt this pandemic.

According to Mel Spigelman, MD, TB Alliance’s President and Chief Executive Officer “TB Alliance is pleased to partner with the Medicines Patent Pool to accelerate R&D and ensure equitable access to new therapies. With its strong track record in negotiating voluntary licenses for HIV treatments, we believe the MPP can contribute significantly toward improving the international response to combatting TB in low- and middle-income countries.”

“The MPP is thrilled to work with TB Alliance, a leading product development partnership in TB and to benefit from its significant expertise in the area of TB drug R&D,” said Greg Perry, Executive Director of the MPP. “This MOU provides an excellent opportunity to bolster both organisations’ efforts, achieve significant global health benefits in the R&D and manufacturing of new anti-TB drugs and facilitate greater and better sharing of IP for that purpose.”

For more information on this, please go to: http://www.tballiance.org/news/tb-alliance-and-medicines-patent-pool-sign-memorandum-understanding-improve-access-tb-medicines

10 Apr 2016


A research team from Stanford University School of Medicine in Palo Alto, California have done some research on a new inexpensive and simple blood test that may assist with improved TB diagnosis as well as the treatment of TB disease. The test identifies a gene expression ‘signature’ that can distinguish between patients with active TB and those with latent TB or other disease.

Limitations in current TB diagnostic methods can lead to incorrect diagnosis; skin prick testing and interferon assays cannot distinguish between patients with active TB and those who are no longer ill or have been vaccinated against the disease, while sputum analysis relies on the patient’s ability to cough up a sample on demand. HIV patients are also prone to misdiagnosis as older tests often fail to pick up active TB in this population.

According to the researchers the new blood test eliminates the need to collect sputum, won’t produce a positive result in the case of a latent infection or previous TB vaccination, and can detect TB in the presence of HIV. They have also indicated that it would be effective irrespective of the TB strain or presence of antibiotic resistance. The test can be used in both children and adults.

For more information on this, please go to: http://consumer.healthday.com